• 关于我们
  • 律师
  • 执业领域
    • 行业
        • 技术、媒体和通信 (TMC)
        • 国际私人财富
        • 房地产、基础设施和能源
        • 生命科学和医疗保健
        • 航空航天与国防
        • 自动化
        • 商业和专业服务
        • 化学制品
        • 消费与零售
        • 金融机构和保险
        • 酒店与休闲
        • 物流与运输
        • 制造业与工业
        • 公共服务和教育
    • 法律服务
        • Artificial intelligence
        • 银行与金融
        • 品牌和广告
        • 商业和消费者合同
        • 竞争、欧盟与贸易
        • 版权和媒体
        • 公司犯罪与合规
        • 国际企业并购与资本市场
        • 数据和网络
        • 纠纷和调查
        • 就业、养老金和流动性
        • 环境规划与监管
        • 环境、社会和公司治理 (ESG)
        • 信息技术
        • Multi-service
        • 专利与创新
        • 私人客户
        • 私募股权
        • 项目、能源和基础设施
        • 房地产与建筑
        • Regulation
        • 重组和破产
        • 税务
        • 风险投资
  • 法域
    • 欧洲
        • 位置
        • 奥地利
        • 比利时
        • 捷克共和国
        • 法国
        • 德国
        • 匈牙利
        • Italy
        • 荷兰
        • 波兰
        • Portugal
        • 爱尔兰共和国
        • 斯洛伐克
        • Spain
        • 英国
        • 乌克兰
          团体
        • CEE Turkish Desk
        • 法国德国团队
        • 办公室
    • 中东和非洲
        • 位置
        • 中东
        • 阿联酋
          团体
        • 非洲团队
        • 以色列团队
        • 办公室
    • 美洲
        • 位置
        • Latin America
        • 美国
          团体
        • 巴西团队
        • 办公室
    • 亚洲
        • 位置
        • 亚洲
        • 中国
        • 韩国
          团体
        • 印度团队
        • 日本团队
        • 办公室
  • 新闻和观点
    • 观点
        • 热点话题
        • Artificial intelligence
        • Data Centre Expertise
        • The EU Whistleblower Directive
        • German Supply Chain Act
        • Unified Patent Court
          Content hub
        • Global Data Hub
        • Interface: 技术、知识产权和媒体法
        • Podcasts
        • Synapse
        • 浏览所有观点
    • 活动
        • 亲自
        • 在线的
        • Browse All Events
    • 新闻
        • 媒体中心
        • 工作亮点
        • 律所新闻
        • 查看全部
  • 职业发展
  • ZH
    • English
    • 中文(简体)
    • Français
    • Deutsch
  • Home
  • People
  • Ross McNaughton
Ross McNaughton
Ross McNaughton

Ross McNaughton

合伙人

  • 剑桥 英国
+44 1223 446 443
vCard
发送电子邮件给我 Call me
奖励

Legal 500 UK 2026

Leading partner in the venture capital, biotechnology and corporate and commercial: Cambridge categories.

Scroll to featured award

Ross is a partner in the Corporate and Life Sciences team, based in our Cambridge office.

Ross is a lead partner within the firm's Tier 1-ranked Biotechnology practice in Cambridge. His practice involves helping life sciences and technology companies as they progress through their life cycle in all aspects of their growth, capital raising and international expansion. As a sector specialist, Ross focuses on biotech, medical devices and diagnostics within Life Sciences, and with the Tech sector supports companies operating in the capital intensive deep tech space, including quantum computing, artificial intelligence, advanced materials, as well as web3.

Ross has extensive experience of a variety of venture and growth financing, public capital raisings, mergers and acquisitions and general corporate advice. Ross was based out of San Francisco, CA in 2018 – 19 and as a result, he has a particular expertise in transactions with a transatlantic component.

专长

执业领域和服务团队

公司/并购与资本市场
风险投资
Artificial intelligence
M&A

行业

酒店与休闲
技术、媒体与通信 (TMC)
加密资产、区块链和分布式账本技术
机器学习

CV

Since 2020 Partner, Taylor Wessing LLP
2015 - 2020 Partner, Penningtons Manches Cooper LLP, Cambridge
2010 - 2015 Partner, Paul Hastings LLP, London
2002 - 2009 Lawyer, Herbert Smith
2018 Admitted as a foreign legal consultant, state bar of California
2004 Admitted as a lawyer, England and Wales
2001 LPC and Post Graduate Degree in Law, Nottingham Law School

职业发展

Since 2020 Partner, Taylor Wessing LLP
2015 - 2020 Partner, Penningtons Manches Cooper LLP, Cambridge
2010 - 2015 Partner, Paul Hastings LLP, London
2002 - 2009 Lawyer, Herbert Smith

教育

2018 Admitted as a foreign legal consultant, state bar of California
2004 Admitted as a lawyer, England and Wales
2001 LPC and Post Graduate Degree in Law, Nottingham Law School

语言

English

奖励

Legal 500 UK 2026

Featured

Leading partner in the venture capital, biotechnology and corporate and commercial: Cambridge categories.

Legal 500 UK 2025

Leading partner

Legal 500 UK 2025

Leading partner

Legal 500 UK 2025

Leading partner

Corporate/M&A (mid-market and private equity) - Band 3: Ross McNaughton heads up the Cambridge corporate department at Taylor Wessing and represents a variety of technology and pharmaceutical clients in complex acquisitions. He also has strong expertise in financing matters. "Ross McNaughton has strong knowledge and sector experience."

‘A strength of Taylor Wessing is the depth of knowledge and expertise across different legal areas, and we were able to access this on a particularly complex transaction under the truly excellent leadership of Ross McNaughton.’ ‘Ross McNaughton and Adrian Toutoungi are our go-to partner specialists.’

Venture capital

Corporate and commercial - Cambridge (Leading individual): "Ross McNaughton was a key negotiating ally in our dealings with both investors and potential acquirers. He was able to lead complex and difficult interactions with third parties in a pragmatic and ultimately successful manner." "Ross McNaughton performed superbly during deal negotiations. His tenacity and ability to direct a legal team is commendable."

Biotechnology

Recognised as a notable practitioner

Venture capital

Experience

Advising on Draig Therapeutics' US$140 million series A financing

We have advised a syndicate of leading global life sciences investors including Access Biotechnology, Canaan Partners and SR One on their landmark US$140 million series A investment in Draig Therapeutics.

Press release
Ross McNaughton
Elinor Picton
Oli Denne
Helen Farr
Adrian Toutoungi
Charlie Adams
Nicholas Vollers
Ed Chapman

Blue Earth Therapeutics on the closing of US$76.5 million Series A funding

We have advised Blue Earth Therapeutics and its management on the closing of US$76.5 million Series A funding. The new funding comes from a broad spectrum of experienced biotech investors and enables Blue Earth Therapeutics to further advance its clinical stage prostate-specific membrane antigen-targeted radioligand therapies.

Press release
Ross McNaughton
Bella Thornton-Clark

Healx raises $47 million in its Series C funding

Advised Healx, an AI-enabled, clinical-stage biotech company specializing in rare diseases based in Cambridge UK, on its $47 million Series C funding. The funding was co-led by Silicon Valley-based R42 Group and Atomico, one of Europe’s largest venture capital firms, with participation from new and existing investors including Balderton, Jonathan Milner, Global Brain, btov, Ayana Capital, o2h and VU Venture Partners.

Press release
Ross McNaughton
Oli Denne
Colin McCall

Advising gene therapy company AlveoGene on its complex spinout and launch investment

We have advised AlveoGene, a new UK gene therapy company on its complex spinout from the Gene Therapy Consortium of Imperial College and the Universities of Oxford and Edinburgh focusing on rare respiratory diseases, as well as on its seed round investment.

Press release
Colin McCall
Ross McNaughton
Bella Thornton-Clark

Advising on transformational life sciences combinations and cross-over rounds

Ross was the lead partner on the transformational roll-up and $250 million cross-over financing of Centessa Pharmaceuticals, representing eight cutting-edge UK and European biotech companies on their participation in a newly established holding company focused on the development of innovative new treatments. Ross was also the lead partner on the combination of three New Science Ventures-backed companies under Ventyx Biosciences Inc in the context of its concurrent $114 million financing led by venBio Partners.

Ross McNaughton

Acting on venture growth rounds for leading life sciences and tech businesses

Ross constantly acts for leading growth companies and investors on their funding rounds, including recently Cambridge Epigenetix on its $88 million series D funding round led by Temasek, Envelop Risk on its $130 million round led by SoftBank, and Oxbotica on its $47 million series B investment.

Ross McNaughton

最新新闻和观点

View Ross's insights
点击此处了解更多
风险投资

Advising on the PhysicsX $135 million Series B financing

2025年7月1日

作者 Ross McNaughton 以及 Oli Denne

Glass.Mapper.Sc.Fields.Image?.Alt
公司/并购与资本市场

Advising on Draig Therapeutics' US$140 million series A financing

2025年6月23日

作者

点击此处了解更多
Glass.Mapper.Sc.Fields.Image?.Alt
酒店与休闲

UK start-ups consider switching to the US for funding

2025年4月23日
Quick read

作者 Ross McNaughton

点击此处了解更多
View Ross's insights

Related news & insights

公司/并购与资本市场

Advising RSM UK on its transatlantic partnership with RSM US and Canada

2025年11月6日

作者

点击此处了解更多
金融服务监管

Financial Services Matters - November 2025

2025年11月6日
In-depth analysis

作者

点击此处了解更多
公司/并购与资本市场

Advising Figment on its acquisition of Rated Labs

2025年11月5日

作者

点击此处了解更多

Getty Images v Stability AI: the trade mark ruling

2025年11月5日
Briefing

作者 Louise Popple

点击此处了解更多
技术、媒体与通信 (TMC)

The Cyber Resilience Act – EU-Wide Requirements for the Cybersecurity of Products

2025年11月3日
In-depth analysis

作者 Mareike Christine Gehrmann 以及 Carla Nelles, LL.M. (Amsterdam)

点击此处了解更多
酒店与休闲

Biotechnology as a security issue: Why dual-use control and adaptive regulation are crucial for national sustainability

2025年11月3日
Quick read

作者 Dr. Niclas von Woedtke, MBA (Kellogg/ WHU)

点击此处了解更多
公司/并购与资本市场

Advising Rezolve AI on its acquisition of Subsquid

2025年11月3日

作者

点击此处了解更多

AI disputes in action

2025年10月31日
点击此处了解更多
纠纷和调查

When intelligent systems fail: a case study in AI liability and the future of commercial disputes

2025年10月31日
In-depth analysis

作者 Katie Chandler 以及 Esha Marwaha

点击此处了解更多
技术、媒体与通信 (TMC)

Advising Careology on its strategic alliance with Boots and Guy's & St Thomas' NHS Foundation Trust

2025年10月31日

作者 Graham Hann 以及 Kelly Burke

点击此处了解更多
View all insights

相关人员

英国
Global

Victoria Hordern

合伙人

伦敦
+44 20 7300 7096
发送电子邮件给我
查看个人资料
Mark Barron

Mark Barron

合伙人

伦敦
硅谷
+44 20 7300 4241
发送电子邮件给我
查看个人资料
josef fuss

Josef Fuss

合伙人

伦敦
+44 20 7300 4110
发送电子邮件给我
查看个人资料

Paul Thorpe

合伙人

伦敦
+44 20 7300 4111
发送电子邮件给我
查看个人资料

Lorraine Smith

Senior Knowledge Lawyer

伦敦
+44 20 7300 7000
发送电子邮件给我
查看个人资料

Phoebe Sennett

律师

伦敦
+44 20 7300 7000
发送电子邮件给我
查看个人资料
Christopher Jeffery

Christopher Jeffery

合伙人

伦敦
+44 20 7300 4230
发送电子邮件给我
查看个人资料

Hannah Elam

律师

伦敦
+44 20 7300 7000
发送电子邮件给我
查看个人资料
jonny bethell

Jonny Bethell

合伙人

伦敦
+44 20 7300 7141
发送电子邮件给我
查看个人资料

Mila Pencheva

高级法律顾问

伦敦
+44 20 7300 7000
发送电子邮件给我
查看个人资料
Full team

Dr. Benedikt Rohrßen

合伙人

慕尼黑
+49 89 21038 0
发送电子邮件给我
查看个人资料
Andrej Leontiev

Andrej Leontiev, LL.M.

合伙人

布拉迪斯拉发
+421 2 5263 2804
发送电子邮件给我
查看个人资料

Jo Joyce

合伙人

都柏林
+353 87 787 0901
发送电子邮件给我
查看个人资料
Dániel Ódor

Dániel Ódor, MRICS

合伙人

布达佩斯
+36 1 32 70 407
发送电子邮件给我
查看个人资料
/Taylor Wessing/Images/People/Profiles/France/Aziere-Charles/Azire-Charles-wit

Charles Azière

律师

巴黎
+33 1 72 74 03 33
发送电子邮件给我
查看个人资料

Susan Hillert, geb. Lipeyko, Lic. en droit (Toulouse I Capitole)

律师

慕尼黑
+49 89 21038 0
发送电子邮件给我
查看个人资料
Rob Hendriks

Rob Hendriks, Dr.

合伙人

阿姆斯特丹
+31 88 02 43 289
发送电子邮件给我
查看个人资料
Lisa-Laura Teunissen

Lisa-Laura Teunissen

律师

阿姆斯特丹
+31 88 024 3225
发送电子邮件给我
查看个人资料

Dannie Hanna

合伙人

都柏林
+353 87 906 0334
发送电子邮件给我
查看个人资料

Jan Rataj

Counsel

布拉格
+420 224 81 92 16
发送电子邮件给我
查看个人资料
Full team

与我会面:

查看所有活动
订阅
  • 关于我们
  • Campaigns and online tools
  • 新闻
  • 律师
  • 执业领域
  • 法域
  • 新闻和观点
  • 活动
  • 媒体中心
  • 联系方式
  • 职业发展
  • 校友
  • 数据保护和隐私政策
  • 网络隐私和 Cookie 政策
  • 监管
  • 有关费用的监管信息
  • 客户投诉程序
  • 使用条款
  • 反奴役宣言
  • 环境
  • 垃圾电子邮件

© Taylor Wessing